Veloxis is a specialty pharmaceutical company committed to helping patients realize the full possibilities of life after transplant. Our sole focus is to develop innovative therapies and programs that provide meaningful support for transplant healthcare providers and the patients they treat.
Veloxis is dedicated to improving patient care through innovative therapies.
Veloxis is committed to patient access and financial support for kidney transplant patients.
Veloxis Pharmaceuticals, Inc. is a wholly owned subsidiary of Asahi Kasei Corporation.
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.